Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women

NCT03144648 · tracked via the Priya Life Science Brazil tracker
Phase
Observational
Started
2012-10-12
Last updated
2025-05-06

Condition(s) studied

Breast Cancer Female

Investigational drug(s) / intervention(s)

lifestyle

lifestyle: Observational study

Study summary

Breast cancer has become a major public health problem in Latin America, as it is the most common form of cancer among women. Women are more likely to develop breast cancer at younger age, and to be diagnosed at an advanced stage compared to western women. Over the past twenty years, the mortality from breast cancer in Latin America has also been increasing very rapidly, and is currently the leading cause of cancer mortality. Little is known on specific risk factors for premenopausal breast cancer in general, and in Latin America in particular. There is a lack of specific knowledge on tumor molecular and pathological characteristics of breast cancer in Latin America premenopausal women, and this has major consequences on cancer treatment and survival.

To improve our understanding on determinants of breast cancer incidence and mortality in young Latin America women and support preventive actions, we implemented an international, population-based multi-center study in Latin America: the PRECAMA study (Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women (PRECAMA): a multicenter population-based case-control study).

PRECAMA is coordinated by the International Agency for Research on Cancer (IARC), and is conducted within 4 Latin American countries: Mexico, Costa Rica, Colombia and Chile. Major aims of the project are the following:

1. To develop a multi-centric population-based case-control study on breast cancer in premenopausal women in several countries in Latin America with structured collection of individual, clinical, pathological information and biological specimens, according to strictly controlled protocols
2. To characterize, in these populations, the subtypes of premenopausal breast cancer on the basis of their molecular and pathological phenotypes
3. To improve the identification of specific endogenous/exogenous factors, and disentangle the interplay of these different factors with regard to breast tumor subtypes.
4. Provide advanced training, induce a structuring effect on the breast cancer research community in Latin America and influence the public health agenda regarding the management of breast cancer.

The results of our study will be of utmost importance to understand the etiology of breast cancer in Latin America countries, and would provide important information on the role of modifiable exposures for breast cancer prevention.

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: * woman between 20 and 45 years old * woman less than 3 years older or younger than the case * living in the area that the study is taking place during the past 3 years * woman menstruated at least once in the past 12 months * woman diagnosed with a primary breast cancer by histopathological examination (only for cases) Exclusion Criteria: * woman receiving tumor treatment, such as radiotherapy, chemotherapy or anti-estrogens (for example, tamoxifen) (except treatment for non-melanoma skin cancers) * woman taking (or has previously taken) any of the following medications in the past 6 months: tamoxifen, Evista (raloxifene), Fareston (toremifene), Aromasin (exemestane), Femara (letrozole), Arimidez (anastrozole) or Megace (megestrol) * woman suffering from chronic kidney failure * woman having a pathology that will hinder adequate communication * woman who is pregnant or nursing * woman who has been previously diagnosed with a cancer(except for non-melanoma skin cancers) * any other reason to exclude

Primary outcome measure(s)

  • breast cancer — at recruitment
    breast cancer

Trial sites (13)

FacilityCityRegionStatus
Barretos Cancer Hospital Barretos Brazil Completed
INC Santiago Independencia Active Not Recruiting
Hso-Crsco Santiago Peñalolén Active Not Recruiting
FALP Santiago Providencia Active Not Recruiting
Grupo Infección y Cáncer. Universidad de Antioquia Medellín Antioquia Recruiting
International Hospital of Colombia Bucaramanga Bucaramanga Recruiting
Facultad de Medicina, Universidad del Norte Barranquilla Colombia Completed
Hospital Internacional de Colombia Fundacion Cardiovascular de Colombia Bucaramanga Colombia Recruiting
SENOSAMA foundation Bucaramanga Colombia Recruiting
Instituto de Oncología HematoOncologos Cali Colombia Completed
Public Health University of Narino Pasto Colombia Recruiting
Agencia Costarricense de Investigaciones Biomédicas (ACIB) San José Provincia de San José Completed
Instituto Nacional de Salud Pública (INSP) Cuernavaca Morelos Completed
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03144648 on ClinicalTrials.gov ↗ ← All trials in Brazil